146 related articles for article (PubMed ID: 16835341)
1. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion.
Leeming DJ; Delling G; Koizumi M; Henriksen K; Karsdal MA; Li B; Qvist P; Tankó LB; Byrjalsen I
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1392-5. PubMed ID: 16835341
[TBL] [Abstract][Full Text] [Related]
2. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
[TBL] [Abstract][Full Text] [Related]
3. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone.
Cloos PA; Lyubimova N; Solberg H; Qvist P; Christiansen C; Byrjalsen I; Christgau S
Clin Lab; 2004; 50(5-6):279-89. PubMed ID: 15209436
[TBL] [Abstract][Full Text] [Related]
4. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
5. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
6. Can bone markers guide more effective treatment of bone metastases from breast cancer?
Clemons M; Cole DE; Gainford MC
Breast Cancer Res Treat; 2006 May; 97(1):81-90. PubMed ID: 16319976
[TBL] [Abstract][Full Text] [Related]
7. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
[TBL] [Abstract][Full Text] [Related]
8. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
[TBL] [Abstract][Full Text] [Related]
9. The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment.
Lüftner D; Günther S; Flath B; Müller C; Echteroff K; Mergenthaler HG; Wernecke KD; Possinger K
Anticancer Res; 1999; 19(4A):2537-44. PubMed ID: 10470191
[TBL] [Abstract][Full Text] [Related]
10. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
[TBL] [Abstract][Full Text] [Related]
11. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.
Cloos PA; Christgau S; Lyubimova N; Body JJ; Qvist P; Christiansen C
Breast Cancer Res; 2003; 5(4):R103-9. PubMed ID: 12818000
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
Takahashi S
Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
[TBL] [Abstract][Full Text] [Related]
14. Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer.
Kiuchi K; Ishikawa T; Hamaguchi Y; Momiyama N; Hasegawa S; Ishiyama A; Kono T; Doi T; Chishima T; Shimada H
Oncol Rep; 2002; 9(3):595-8. PubMed ID: 11956634
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
16. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
Garnero P; Schott AM; Prockop D; Chevrel G
Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
[TBL] [Abstract][Full Text] [Related]
17. Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases.
Voorzanger-Rousselot N; Journe F; Doriath V; Body JJ; Garnero P
Calcif Tissue Int; 2009 May; 84(5):348-54. PubMed ID: 19252761
[TBL] [Abstract][Full Text] [Related]
18. [The biochemical markers of bone remodeling in cancer patients with skeletal involvement].
Liubimova NV; Bronnikov IIu; Robins SP; Trapeznikova MF; Kushlinskiĭ NE
Vopr Onkol; 2000; 46(3):290-7. PubMed ID: 10976274
[TBL] [Abstract][Full Text] [Related]
19. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases.
Walls J; Assiri A; Howell A; Rogers E; Ratcliffe WA; Eastell R; Bundred NJ
Br J Cancer; 1999 Jun; 80(8):1265-70. PubMed ID: 10376982
[TBL] [Abstract][Full Text] [Related]
20. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
